Name: Xerophthalmia Treatment Market Size Share | Industry Insights 2023
Creator: DataM Intelligence
Published: Fri Jan 06 2023 17:39:44 GMT+0530 (India Standard Time)
License: https://www.datamintelligence.com/terms-conditions
Keywords: Xerophthalmia treatment market

Xerophthalmia Treatment Market Size Share | Industry Insights 2023

Xerophthalmia Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Xerophthalmia Treatment Market is Segmented&nbsp;By Type&nbsp;(Artificial Tears, Cyclosporin, Oral Corticosteroids, Punctal Plugs, Omega Supplements, Others), By Distribution Channel&nbsp;(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

<blockquote>
Xerophthalmia Treatment Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of&nbsp; 6.2% during the forecast period (2023-2030).
</blockquote>

Xerophthalmia is a medical condition in which the eye fails to produce tears. It could be caused by vitamin A deficiency, which is a term that is sometimes used to describe the condition, but other factors could also cause it.

<h3>Xerophthalmia Treatment Market&nbsp;Dynamics</h3>

The factors influencing the global xerophthalmia treatment market are the increasing demand for xerophthalmia treatment and the growing prevalence of xerophthalmia.

The increasing demand for xerophthalmia treatment is expected to drive the market growth

Xerophthalmia can affect people of any age group, but it is most common in preschoolers, adolescents, and pregnant women. On the other hand, children are more susceptible to vitamin A deficiency and xerophthalmia due to their higher vitamin A requirements for growth.

Intestinal infestations and infections are also more common in children, impair vitamin A absorption and cause it to be lost.

Vitamin A therapy or supplementation is the most common treatment for xerophthalmia. Vitamin A can be taken orally or administered intravenously. Other medications, such as antibiotics, may be prescribed by the doctor to prevent eye infections. Vitamin A therapy is used to treat xerophthalmia in both adults and children. The dose is determined by the patient&#39;s age and the severity of their xerophthalmia. The doctor may also advise the patients to consume plenty of beta-carotene-rich yellow fruits and vegetables. They can also suggest that the patient eat more green leafy vegetables, meat, and dairy. If other factors cause xerophthalmia, the doctor may work with the patient to address the underlying issue.

Limitations associated with xerophthalmia treatment are expected to hamper the market growth

Accurate doses of treatment should be administered in patients suffering from xerophthalmia. If not, it can hamper market growth. For instance, vitamin A (retinol) PO, except in pregnant women, treatment is the same regardless of the clinical stage. The capsules as a whole should not be swallowed. The capsule should be opened and placed directly into the mouth. Vitamin A deficiency in breastfed infants younger than 6 months is uncommon. Moreover, to avoid overdosing, keep track of all doses given on the health/immunization card and do not exceed the recommended doses. Overdosing on vitamin A can result in increased intracranial pressure (bulging fontanelle in infants; headache, nausea, vomiting) and impaired consciousness and convulsions in severe cases. These side effects are temporary, and they require medical monitoring and, if necessary, symptomatic treatment.

<h3>COVID-19 Impact Analysis</h3>

The covid-19 outbreak has affected many sectors. Especially the economy all over the world.And will also affect the xerophthalmia treatment, market-creating supply chain, and market 
disruption, affecting production and demand. Amidst the COVID-19 crisis and social distancing recommendations, general visits to an ophthalmologist have decreased.This might affect the market.A recent study has shown that the number of general medical emergency departments (ED)visits have declined 42% during the early COVID-19 pandemic. Another recent study hasshown that during the national lockdown in Italy, the number of total visits to an eye-specificED in Bologna, Italy, decreased. Hence, the global xerophthalmia treatment market is expected to be impacted.

<h3>Xerophthalmia Treatment Market Segment Analysis</h3>

The artificial tears segment is expected to dominate the market growth in the forecast period

Xerophthalmia treatment includes nonprescription eye drops and ointments to relieve the eyes, such as artificial, preservative-free tears, and similar to natural tears. It&#39;s important to remember that not all tear products are created equal, and each patient&#39;s needs differ slightly. Some of these products are aqueous and provide temporary relief from symptoms.

Preservative-free artificial tears are more frequently recommended because they provide more relief and do not irritate the eyes. Avoid products that claim to remove redness or &quot;whiten&quot; the eyes because they lack the necessary moisturizing properties and often exacerbate the problem. In more serious cases, an ophthalmologist may place special caps in the lacrimal punctum to keep natural and artificial tears from draining out (with either temporary collagen caps that will be absorbed or permanent silicone caps). People with xerophthalmia should avoid dust, pollen, smoking, and other polluting factors in the environment. Furthermore, their prolonged exposure to extreme heat will exacerbate xerophthalmia. On the other hand, interior moisturizers can help because they add moisture to the skin, which helps to prevent tear evaporation.

Xerophthalmia Treatment Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			6.2%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Type,&nbsp;By Distribution Channel, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

<h3>Xerophthalmia Treatment Market Geographical Analysis</h3>

Asia Pacific region is expected to hold the largest market share in the global xerophthalmia treatment market

The growing prevalence of xerophthalmia and increasing micronutrient deficiency are expected to drive this region&#39;s market growth. According to estimates, 1.02 billion people worldwide are severely deficient in micronutrients, with vitamin A being the most deficient nutrient in the body. According to similar studies, India is home to 85 percent of all South Asian children with xerophthalmia. In developing countries, vitamin A deficiency is a major, preventable nutritional issue. Vitamin A deficiency is thought to be responsible for the blindness of 30-40,000 children in India. Among South Asian countries, India has the highest prevalence of clinical and subclinical VAD, with 62 percent of preschool children being vitamin A deficient. These startling findings pointed to a high mortality rate, with 330,000 children dying each year. According to estimates, subclinical VAD affects 31 percent to 57 percent of preschool children.

<h3>Xerophthalmia Treatment Market Competitive Landscape</h3>

Xerophthalmia Treatment Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Allergan Plc, Akorn, Inc, Thea Pharmaceuticals Limited, OASIS Medical, Scope Ophthalmics Ltd., Medicom Healthcare Ltd, FDC Limited, Jamjoom Pharmaceuticals Co., Sentiss Pharma Private Limited, Johnson &amp; Johnson Inc.

Allergan Plc

Overview: Allergan plc is an American pharmaceutical company headquartered in Dublin, Ireland. It acquires, develops, manufactures, and markets brand-name drugs and medical devices in medical aesthetics, eye care, central nervous system, and gastroenterology. The company was founded in 2013.

Product Portfolio: The ophthalmic emulsions RESTASIS and RESTASIS MultiDose(cyclosporine ophthalmic emulsion) help increase the eyes&#39; natural ability to produce tears, which inflammation caused by chronic dry eye.

<h3 style="background:#eeeeee;border:1px solid #cccccc;padding:5px 10px;">Frequently Asked Questions</h3>

What is the Projected CAGR value of the Xerophthalmia Treatment Market?

Xerophthalmia Treatment Market is expected to grow at a&nbsp;CAGR of 6.2%&nbsp;during the forecasting period 2023-2030.

Which region controlled the global market during 2023-2030?

North America&nbsp;region Controls&nbsp;the&nbsp;Xerophthalmia Treatment Market&nbsp;during 2023-2030

Which is the fastest growing region in the Xerophthalmia Treatment Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period.

<h3 style="background:#eeeeee;border:1px solid #cccccc;padding:5px 10px;">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/pet-food-market">Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/organic-pet-food-market">Organic Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/freeze-dried-pet-food-market">Freeze-Dried Pet Food Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>Methodology and Scope

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet By Type</li>
		<li>Market Snippet By Distribution Channel</li>
		<li>Market Snippet By Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers:
			<ol>
				<li>The increasing demand for xerophthalmia treatment</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Limitations associated with xerophthalmia treatment</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis 
	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>By Type
	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
		<li>Market Attractiveness Index, By Type
		<ol>
			<li>Artificial Tears*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
			</ol>
			</li>
			<li>Cyclosporin</li>
			<li>Oral Corticosteroids</li>
			<li>Punctal Plugs</li>
			<li>Omega Supplements</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029<a name="_Hlk95398897"></a></li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>&nbsp;Online Pharmacies</li>
		<li>Other</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>&nbsp;Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Allergan Plc*
		<ol>
			<li>&nbsp;Company Overview</li>
			<li>&nbsp;Product Portfolio and Description</li>
			<li>&nbsp;Key Highlights</li>
			<li>&nbsp;Financial Overview</li>
		</ol>
		</li>
		<li>Akorn, Inc</li>
		<li>Thea Pharmaceuticals Limited</li>
		<li>OASIS Medical</li>
		<li>Scope Ophthalmics Ltd.</li>
		<li>Medicom Healthcare Ltd</li>
		<li>FDC Limited</li>
		<li>Jamjoom Pharmaceuticals Co.</li>
		<li>Sentiss Pharma Private limited</li>
		<li>Johnson &amp; Johnson Inc.(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM&nbsp;&nbsp;Intelligence
	<ol>
		<li>&nbsp;Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01Global Xerophthalmia Treatment Market, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table 02 Global Xerophthalmia Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table 03 Global Xerophthalmia Treatment Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 04 Global Xerophthalmia Treatment Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table 05Global Xerophthalmia Treatment Market Value, By Type, 2021-2029($ Million)

Table 06 Global Xerophthalmia Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table 07&nbsp;Global Xerophthalmia Treatment Market Value, By Distribution Channel, 2021-2029($ Million)

Table 08 Global Xerophthalmia Treatment Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 09 Global Xerophthalmia Treatment Market Value, By Region, 2021-2029($ Million)

Table 10North America Xerophthalmia Treatment Market Value, By Type, 2021-2029($ Million)

Table 11&nbsp;North America Xerophthalmia Treatment Market Value, By Distribution Channel, 2021-2029($ Million)

Table 12North America Xerophthalmia Treatment Market Value, By Country, 2021-2029($ Million)

Table 13South America Xerophthalmia Treatment Market Value, By Type, 2021-2029($ Million)

Table 14South America Xerophthalmia Treatment Market Value, By Distribution Channel, 2021-2029($ Million)

Table 15South America Xerophthalmia Treatment Market Value, By Country, 2021-2029($ Million)

Table 16Europe Xerophthalmia Treatment Market Value, By Type, 2021-2029($ Million)

Table 17Europe Xerophthalmia Treatment Market Value, By Distribution Channel, 2021-2029($ Million)

Table 18Europe Xerophthalmia Treatment Market Value, By Country, 2021-2029($ Million)

Table 19Asia-Pacific Xerophthalmia Treatment Market Value, By Type, 2021-2029($ Million)

Table 20Asia-Pacific Xerophthalmia Treatment Market Value, By Distribution Channel, 2021-2029($ Million)

Table 21Asia-Pacific Xerophthalmia Treatment Market Value, By Country, 2021-2029($ Million)

Table 22Middle East &amp; Africa Xerophthalmia Treatment Market Value, By Type, 2021-2029($ Million)

Table 23Middle East &amp; Africa Xerophthalmia Treatment Market Value, By Distribution Channel, 2021-2029($ Million)

Table 24Allergan Plc: Overview

Table 25Allergan Plc: Product Portfolio

Table 26Allergan Plc: Key Developments

Table 27Akorn, Inc: Overview

Table 28Akorn, Inc: Product Portfolio

Table 29Akorn, Inc: Key Developments

Table 30Thea Pharmaceuticals Limited: Overview

Table 31Thea Pharmaceuticals Limited: Product Portfolio

Table 32Thea Pharmaceuticals Limited: Key Developments

Table 33OASIS Medical: Overview

Table 34OASIS Medical: Product Portfolio

Table 35OASIS Medical: Key Developments

Table 36Scope Ophthalmics Ltd.: Overview

Table 37Scope Ophthalmics Ltd.: Product Portfolio

Table 38Scope Ophthalmics Ltd.: Key Developments

Table 39Medicom Healthcare Ltd: Overview

Table 40 Medicom Healthcare Ltd: Product Portfolio

Table 41Medicom Healthcare Ltd: Key Developments

Table 42FDC Limited: Overview

Table 43FDC Limited: Product Portfolio

Table 44 FDC Limited: Key Developments

Table 45Jamjoom Pharmaceuticals Co.: Overview

Table 46 Jamjoom Pharmaceuticals Co.: Product Portfolio

Table 47Jamjoom Pharmaceuticals Co.: Key Developments

Table 48 Sentiss Pharma Private limited: Overview

Table 49 Sentiss Pharma Private limited: Product Portfolio

Table 50Sentiss Pharma Private limited: Key Developments

Table 51Johnson &amp; Johnson Inc.: Overview

Table 52Johnson &amp; Johnson Inc.: Product Portfolio

Table 53Johnson &amp; Johnson Inc.: Key Developments

List of Figures

Figure 01 Global Xerophthalmia Treatment Market Share, By Type, 2021 &amp; 2029 (%)

Figure 02 Global Xerophthalmia Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 03 Global Xerophthalmia Treatment Market Share, By Region, 2021 &amp; 2029 (%)

Figure 04 Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 05 Global Xerophthalmia Treatment Market Y-o-Y Growth By Type, 2021-2029 (%)

Figure 06 Artificial Tears: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 07 Cyclosporin: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 08 Oral Corticosteroids: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 09 Punctal Plugs: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 10 Omega Supplements: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 11 Other: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 12 Global Xerophthalmia Treatment Market Y-o-Y Growth By Distribution Channel, 2021-2029 (%)

Figure 13 Hospital Pharmacies: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 14 Retail Pharmacies: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 15 Online Pharmacies: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 16 Other: Global Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 17 Global Xerophthalmia Treatment Market Y-o-Y Growth By Region, 2021-2029 (%)

Figure 18 North America Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 19 North America Xerophthalmia Treatment Market Share, By Type, 2021 &amp; 2029 (%)

Figure 20 North America Xerophthalmia Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 21 North America Xerophthalmia Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 22 South America Xerophthalmia Treatment Market Share, 2021-2029($ Million)

Figure 23 South America Xerophthalmia Treatment Market Share, By Type, 2021 &amp; 2029 (%)

Figure 24 South America Xerophthalmia Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 25 South America Xerophthalmia Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 26 Europe Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 27 Europe Xerophthalmia Treatment Market Share, By Type, 2021 &amp; 2029 (%)

Figure 28 Europe Xerophthalmia Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 29 Europe Xerophthalmia Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 30 Asia-Pacific Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 31 Asia-Pacific Xerophthalmia Treatment Market Share, By Type, 2021 &amp; 2029 (%)

Figure 32 Asia-Pacific Xerophthalmia Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 33 Asia-Pacific Xerophthalmia Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 34 Middle East &amp; Africa Xerophthalmia Treatment Market Value, 2021-2029($ Million)

Figure 35 Middle East &amp; Africa Xerophthalmia Treatment Market Share, By Type, 2021 &amp; 2029 (%)

Figure 36 Middle East &amp; Africa Xerophthalmia Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 37 Allergan Plc: Financials

Figure 38 Akorn, Inc: Financials

Figure 39 Thea Pharmaceuticals Limited: Financials

Figure 40 OASIS Medical: Financials

Figure 41 Scope Ophthalmics Ltd.: Financials

Figure 42 Medicom Healthcare Ltd: Financials

Figure 43 FDC Limited: Financials

Figure 44 Jamjoom Pharmaceuticals Co.: Financials

Figure 45 Sentiss Pharma Private limited: Financials

Figure 46 Johnson &amp; Johnson Inc.: Financials